ABSTRACT
To evaluate the clinical curative effect of Compound Biejia Ruangan Tablets (CBRT) combined with Adefovir Dipivoxil in the treatment of chronic hepatitis B with liver fibrosis using Meta-analysis. Cochrane library, PubMed, CNKI, Wanfang databases, and VIP were retrieved comprehensively to collect randomized controlled trials (RCTs) of CBRT combined with Adefovir Dipivoxil in the treatment of chronic hepatitis B with hepatic fibrosis from their inception to October 2017. treatment group was treated with CBRT combined with Adefovir Dipivoxil, and the control group was treated with Adefovir Dipivoxil. All the data were analyzed using Revman 5.3. A total of 19 RCTs and 1 776 patients were included. Meta-analysis results showed that the serum indexes including HA, IV-C, LN, PCIII, ALT, AST, and TBIL of the treatment group, were significantly lower than those of control group. HA [SMD = -1.72, 95% CI (-2.26, -1.17), P = 0.000 01]; IV-C [SMD = -1.10, 95% CI (-1.66, -0.54), P = 0.000 10]; LN [SMD = -1.18, 95% CI (-1.64, -0.73), P = 0.000 01]; PCIII [SMD = -1.52, 95% CI (-1.97, -1.07), P = 0.000 01]; ALT [SMD =-0.48, 95% CI (-0.68, -0.28), P = 0.000 01]; AST [SMD = -1.19, 95% CI (-2.08, -0.29), P = 0.010 00]; TBIL [SMD = -0.98, 95%CI (-1.38, -0.58), P = 0.000 01]; There were no significant difference in serum HBV DNA, and HbeAg negative conversion rate treatment group compared with control group. HBV DNA [RR = 1.21, 95% CI (0.97, 1.50), P = 0.09]; HBeAg [RR = 1.05, 95% CI (0.82, 1.34), P = 0.70]; The total clinical effective treatment group was significantly better than control group. [RR = 1.25, 95% CI (1.15, 1.36), P = 0.000 01]. Compared with the single use of Adefovir Dipivoxil, the clinical curative effect of CBRT combined with Adefovir Dipivoxil in the treatment of chronic hepatitis B with liver fibrosis is better,which can significantly reduce the level of serum liver fiber markers and improve liver function in patients with biochemical indicators and the total clinical efficiency.
ABSTRACT
OBJECTIVE:To observe the effects of Compound biejia ruangan tablets combined Entecavir tablets on liver func-tion and hematoidin of patients with chronic hepatitis B(CHB)blood stasis syndrome. METHODS:Totally 110 patients with CHB blood stasis syndrome were selected from Neijiang Second People's Hospital,the Affiliated Hospital of Southwest Medical Univer-sity and Yibin First People's Hospital during Jan.-Dec. 2015. They were divided into control group and observation group by strati-fied blocked randomitation,with 55 cases in each group. Control group was given Entecavir tablets 0.5 mg,po,qd;observation group was additionally given Compound biejia ruangan tablets 2.0 g,po,tid. Both groups received treatment for 12 months. TCM syndrome scores,the levels of liver function indexes(AST,ALT,ALP,GGT),serum bilirubin(TBIL,DBIL,IBIL),liver fi-brosis indexes(LN,HA,PⅢP,Ⅳ-C)and Fibroscan(FS)were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS:In observation group,2 patients withdrew from the study,and 3 patients of control group with-drew from the study. Before treatment,there was no statistical significance in TCM syndrome scores,the levels of liver function in-dexes,serum bilirubin,liver fibrosis indexes and FS between 2 groups(P>0.05). After treatment,TCM syndrome scores,the lev-els of TBIL,IBIL,LN,HA,PⅢP,Ⅳ-C and FS in 2 groups were significantly decreased,while DBIL level was increased signifi-cantly,and the observation group was significantly better than control group,with statistical significance(P<0.05). The levels of AST and ALT in observation group were decreased significantly,while the levels of ALP and GGT were increased significantly, and the observation group was significantly better than control group,with statistical significance(P<0.05). There was no statisti-prove liver function indexes and bilirubin level,and inhibit liver fibrosis with good safety.